Overall shareholder base voted to maintain £201m trust
Main focus on pharma and biotech
Deal would create Europe's largest ETF provider
£300m fundraise recently completed
Ninety One and Man GLG offerings removed
Investment objectives remain unchanged
UK residency for tax purposes settled